Evidence map›Paper›PMID 38727343›Full record

ArticleNanomaterials (Basel, Switzerland)2024

Characterization of a Chimeric Resilin-Elastin Structural Protein Dedicated to 3D Bioprinting as a Bioink Component.

Violetta Cecuda-Adamczewska, Agnieszka Romanik-Chruścielewska, Katarzyna Kosowska, Natalia Łukasiewicz, Iwona Sokołowska, Paulina Korycka, Katarzyna Florys-Jankowska, Agnieszka Zakrzewska, Michał Wszoła, Marta Klak

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Violetta Cecuda-AdamczewskaFoundation of Research and Science Development, 01-424 Warsaw, Poland.ORCID 0000-0001-6967-2970
Agnieszka Romanik-ChruścielewskaFoundation of Research and Science Development, 01-424 Warsaw, Poland.
Katarzyna KosowskaFoundation of Research and Science Development, 01-424 Warsaw, Poland.
Natalia ŁukasiewiczFoundation of Research and Science Development, 01-424 Warsaw, Poland.
Iwona SokołowskaFoundation of Research and Science Development, 01-424 Warsaw, Poland.
Paulina KoryckaFoundation of Research and Science Development, 01-424 Warsaw, Poland.
Katarzyna Florys-JankowskaFoundation of Research and Science Development, 01-424 Warsaw, Poland.
Agnieszka ZakrzewskaPolbionica Ltd., 01-424 Warsaw, Poland.
Michał WszołaPolbionica Ltd., 01-424 Warsaw, Poland.
Marta KlakPolbionica Ltd., 01-424 Warsaw, Poland.ORCID 0000-0003-3901-586X

Funding

The National Centre for Research and Development TECHMATSTRATEG-III/0027/2019-00/
6 · The paper itself

Abstract

In this study we propose to use for bioprinting a bioink enriched with a recombinant RE15mR protein with a molecular weight of 26 kDa, containing functional sequences derived from resilin and elastin. The resulting protein also contains RGD sequences in its structure, as well as a metalloproteinase cleavage site, allowing positive interaction with the cells seeded on the construct and remodeling the structure of this protein in situ. The described protein is produced in a prokaryotic expression system using an

Indexed as

3D bioprintingcytotoxicityrecombinant proteinsresilin- and elastin-like engineered polypeptide

Identifiers

PMID38727343
PMCPMC11085090

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.